Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

National Institute of Allergy and Infectious Diseases

Investor type Government Office


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 79
Average round size
The average size of a deal this fund participated in
Portfolio companies 66
Rounds per year 0.59
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 5
Key employees Soon
Stages of investment

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Life Science

In 1887 was created National Institute of Allergy and Infectious Diseases, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the Bethesda.

Among the various public portfolio startups of the fund, we may underline BlueWillow Biologics, Nirvana Science, Inc., Rutgers Universityu2013New Brunswick Besides, a startup needs to be aged more than 20 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Education, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups.

The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the National Institute of Allergy and Infectious Diseases, startups are often financed by Venture Investors, VentureSouth, Perseus. The meaningful sponsors for the fund in investment in the same round are National Institutes of Health, US Department of Energy, National Science Foundation. In the next rounds fund is usually obtained by University of Michigan MINTS fund, Small Business Innovation Research, North Coast Technology Investors.

The high activity for fund was in 2019. Speaking about the real fund results, this Corporate Investor is 72 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Case Western Reserve University - Crunchbase School Profile & Alumni

$3M30 Nov 2022 Cleveland, Ohio, United States

The Baruch S. Blumberg Institute

$5M21 Nov 2022 Doylestown, Pennsylvania, United States

Duke Human Vaccine Institute

Health Diagnostics
$25M11 Oct 2022 Durham, North Carolina, United States

Aldatu Biosciences

Health Care
$3M12 Sep 2022 Boston, Massachusetts, United States

UAMS Health

Health Care
Non Profit
$3M25 Aug 2022 Little Rock, Arkansas, United States

Institute for Bioscience and Biotechnology Research

$6M22 Aug 2022 Rockville, Maryland, United States

Melax Technologies

Artificial Intelligence
Domain Registrar
Machine Learning
$300K10 Aug 2022 Houston, Texas, United States

7 Hills Pharma

Health Care
$3M01 Aug 2022 Houston, Texas, United States

Intact Genomics

Clinical Trials
Medical Device
$2M01 Jul 2022 Illinois, United States
Phase Genomics to Develop Commercial Platform for the Discovery of New Viruses with $1.7 Million Grant

– Phase Genomics, Inc. announced the receipt of a $1.7MM grant from the National Institute of Allergy and Infectious Diseases (NIAID).
– This funding will fuel the commercialization of a first-in-class solution for the discovery of DNA viruses, employing a novel reagent kit and robust software platform that leverages Phase Genomics’ proprietary Hi-C technology.
Phase Genomics is also funded by revenue from sales of its proximity ligation (Hi-C) kits, scientific services, and computational analysis.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent National Institute of Allergy and Infectious Diseases?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: